Trials / Recruiting
RecruitingNCT06978114
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a clinical study to explore the efficacy and safety of BL-B01D1+PD-1/PD-L1 monoclonal antibody in patients with advanced biliary tract cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-B01D1 | Administration by intravenous infusion for a cycle of 3 weeks. |
| DRUG | Pembrolizumab | Administration by intravenous infusion for a cycle of 3 weeks. |
Timeline
- Start date
- 2025-06-10
- Primary completion
- 2027-05-01
- Completion
- 2027-12-01
- First posted
- 2025-05-18
- Last updated
- 2025-07-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06978114. Inclusion in this directory is not an endorsement.